Abstracts

Citation

Stuart E. Starr, M.D., Courtney V. Fletcher, Pharm.D., Stephen A. Spector, M.D., Richard Brundage, Pharm.D., Ph.D., Florence H. Yong, M.S., Steven D. Douglas, M.D., Douglas J. Manion, M.D., F.R.C.P. Efavirenz (EFV) Liquid Suspension in Combination with Nelfinavir and Nucleoside Reverse Transcriptase Inhibitors (NTRIs) in HIBV-Infected Children.

Citation

Stuart E. Starr, M.D., Courtney V. Fletcher, Pharm.D., Stephen A. Spector, M.D., Richard Brundage, Pharm.D., Ph.D., Florence H. Yong, M.S., Douglas J. Manion, M.D., F.R.C.P. Efavirenz in Combination with Nelfinavir and Nucleoside Reverse Transcriptase Inhibitors is Safe and Virologically Effective in HIV-Infected Children.

Citation

Efavirenz Pharmacokinetics during the 3rd Trimester of Pregnancy and Postpartum. Presented at: 18th Conference on Retroviruses & Opportunistic Infections.

Citation

Marije Van Schalkwyk, Adrie Bekker, Eric Decloedt, Jiajia Wang, David E. Shapiro, Tim R. Cressey, Gerhard B. Theron, Mark F. Cotton, Renee Browning, Tara DeYampert, Edmund V. Capparelli, Alice M. Stek, Mark Mirochnick, Brookie M. Best, Ahizechukwu C. Eke, IMPAACT P1026s Protocol Team. Efavirenz Pharmacokinetics in Pregnancy and Postpartum With and Without First-line Tuberculosis Drugs. Presented at: CROI 2026; 2026 Feb 25.

Citation

Richard M. Rutstein, M.D., Pearl Samson, M.S., Grace M. Aldrovandi, MD, Bobbie L. Graham, B.S., Steven M. Schnittman, M.D., Elizabeth (Betsy) Smith, M.D., Lynne M. Mofenson, M.D., F.A.A.P., Terence Fenton, Ed.D. Effect of atazanavir (ATV) on serum cholesterol (CH) and triglyceride (TG) levels in HIV-infected infants, children, and adolescents: Pediatric AIDS Clinical Trials Group (PACTG) 1020A. Presented at: 12th Conference on Retroviruses and Opportunistic Infections.

Citation

Effect of HAART on tuberculosis (TB) incidence in HIV-infected infants with early HIV disease enrolled in a prospective TB prevention trial. Presented at: 20th Conference on Retroviruses and Opportunistic Infections.

Citation

Edmund Capparelli, Pharm.D., Francesca Aweeka, Pharm.D., Brookie M. Best, Pharm.D., ChengCheng Hu, Ph.D., Jane Hitti, M.D., M.P.H., Lisa M. Frenkel, M.D., Alice M. Stek, M.D., Mark Mirochnick, M.D. Effect of pregnancy on nevirapine pharmacokinetics during chronic therapy. Presented at: 6th Int'l Workshop on Clinical Pharmacology of HIV Therapy.

Citation

Effect of Pregnancy on Pharmacokinetics of Boosted Indinavir. Presented at: 13th International Workshop on Clinical Pharmacology of HIV Therapy.

Citation

Hulin Wu, Ph.D., A. A. Ding, John L. Sullivan, M.D., Katherine Luzuriaga, M.D. Effect Of Treatment Efficacy and Treatment Time On HIV-1 Dynamics.

Citation

Pearl Samson, M.S., Richard M. Rutstein, M.D., Steven M. Schnittman, M.D., Alberto A. Ortiz, M.S., Bobbie L. Graham, B.S., Terence Fenton, Ed.D., Grace M. Aldrovandi, MD. Effects of Antiretroviral Exposure and Genotypic Mutations in Predicting Phenotypic Resistance to Atazanavir (ATV), Lopinavir (LPV), and Tenofovir (TDF) in Patients Naive to these Drugs. Presented at: 13th Symposium on HIV and Emerging Infectious Diseases; 2004 Jun 14.